Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Humacyte Inc (NASDAQ: HUMA) closed at $1.29 in the last session, up 2.38% from day before closing price of $1.26. In other words, the price has increased by $2.38 from its previous closing price. On the day, 3.22 million shares were traded. HUMA stock price reached its highest trading level at $1.31 during the session, while it also had its lowest trading level at $1.23.
Ratios:
We take a closer look at HUMA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.62.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on August 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $3.50.
H.C. Wainwright reiterated its Buy rating for the stock on December 20, 2024, while the target price for the stock was revised from $12 to $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when Dougan Brady W sold 1,100,000 shares for $1.63 per share. The transaction valued at 1,793,000 led to the insider holds 591,685 shares of the business.
Dougan Brady W sold 549,360 shares of HUMA for $1,005,329 on Aug 18 ’25. The Director now owns 1,691,685 shares after completing the transaction at $1.83 per share. On Aug 20 ’25, another insider, Dougan Brady W, who serves as the Director of the company, sold 591,685 shares for $1.58 each. As a result, the insider received 934,862 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 241580000 and an Enterprise Value of 273063008. For the stock, the TTM Price-to-Sale (P/S) ratio is 153.87. Its current Enterprise Value per Revenue stands at 173.815 whereas that against EBITDA is -2.806.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.90, which has changed by -0.7193764 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $6.77, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -16.46%, while the 200-Day Moving Average is calculated to be -35.63%.
Shares Statistics:
According to the various share statistics, HUMA traded on average about 5.18M shares per day over the past 3-months and 4240830 shares per day over the past 10 days. A total of 158.84M shares are outstanding, with a floating share count of 158.02M. Insiders hold about 15.62% of the company’s shares, while institutions hold 24.69% stake in the company. Shares short for HUMA as of 1763078400 were 33414650 with a Short Ratio of 6.46, compared to 1760486400 on 27220587. Therefore, it implies a Short% of Shares Outstanding of 33414650 and a Short% of Float of 20.02.
